Abbott LaboratoriesABT is slated to report second-quarter 2025 results on July 17, before the opening bell. The company ...

The device focuses on examining sonoporation-based drug delivery that involves ultrasound-based treatment with microbubbles.

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 ...

The global Brain Pacemaker Market represents a rapidly expanding segment of the medical device industry, valued at USD 3.66 ...

Air pollutants like ozone and nitrogen dioxide can cause inflammation in the nerves that play a role in migraines. Bright sunlight can also be especially bothersome, likely due to heightened ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

(MENAFN- GetNews) The Key Neuromodulation companies in the market include - Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Abbott’s neuromodulation medical director says the company’s spinal cord stimulator, which won gold at the 2025 Edison Awards, is small but mighty.

Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, expectations were $1.07.